First batch of HyNap-Dasa tablets manufactured on commercial scale according to GMP
STOCKHOLM – December 19, 2019. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the first batch of HyNap-Dasa tablets has now been manufactured on commercial scale. The tablets are intended for the regulatory stability studies that are necessary for an ANDA application. The development of the company's first product candidate HyNap-Dasa, an amorphous version of Sprycel® (dasatinib), continues according to plan.Xspray Pharma's CMO (Contract Manufacturing Organization) in the US, for the manufacturing of final tablets, has now produced the first batch of commercial-